Clinical Trial Update: CDD Plus Bortezomib or CDDin Relapsed or Refractory Multiple Myeloma With Extramedullary Plasmacytoma [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial is evaluating a CDD-based regimen with Bortezomib versus CDD alone in relapsed or refractory multiple myeloma with extramedullary plasm…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extramedullary Plasmacytoma
• Multiple Myeloma

Drugs mentioned

• Bortezomib (bortezomib)

Snippet

Sponsor: Beijing Chao Yang Hospital | Conditions: Extramedullary Plasmacytoma | Phase 3 | Status: UNKNOWN